InfuSystem (NYSEAMERICAN:INFU) Rating Lowered to Buy at StockNews.com

InfuSystem (NYSEAMERICAN:INFU) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.

InfuSystem Stock Down 6.0 %

INFU traded down $0.49 during trading on Monday, hitting $7.63. The company’s stock had a trading volume of 23,945 shares, compared to its average volume of 43,762. The company has a current ratio of 1.95, a quick ratio of 1.54 and a debt-to-equity ratio of 0.56. The firm has a market cap of $162.21 million, a P/E ratio of 254.42 and a beta of 1.24. InfuSystem has a twelve month low of $7.57 and a twelve month high of $11.44.

Institutional Trading of InfuSystem

Several institutional investors have recently modified their holdings of the stock. First Eagle Investment Management LLC boosted its holdings in InfuSystem by 29.6% in the 3rd quarter. First Eagle Investment Management LLC now owns 468,400 shares of the medical instruments supplier’s stock worth $4,515,000 after buying an additional 107,001 shares during the last quarter. Heartland Advisors Inc. boosted its stake in shares of InfuSystem by 17.6% in the third quarter. Heartland Advisors Inc. now owns 500,000 shares of the medical instruments supplier’s stock worth $4,820,000 after acquiring an additional 75,000 shares during the last quarter. Ranger Investment Management L.P. boosted its stake in shares of InfuSystem by 4.7% in the fourth quarter. Ranger Investment Management L.P. now owns 689,842 shares of the medical instruments supplier’s stock worth $7,271,000 after acquiring an additional 30,835 shares during the last quarter. Punch & Associates Investment Management Inc. increased its position in shares of InfuSystem by 3.2% during the third quarter. Punch & Associates Investment Management Inc. now owns 939,918 shares of the medical instruments supplier’s stock worth $9,061,000 after purchasing an additional 28,807 shares in the last quarter. Finally, Citigroup Inc. raised its stake in InfuSystem by 124.1% in the 3rd quarter. Citigroup Inc. now owns 50,640 shares of the medical instruments supplier’s stock valued at $488,000 after purchasing an additional 28,038 shares during the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.